A Multi-National Prospective non interventional study of standard of care in participants with MM who are refractory to at least one Proteasome inhibitor, one immunmodulatory  Drug and one anti-CD38 antibody

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy 

A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma 

Nicht – interventionelle prospektive Unbedenklichkeits – Studie im Rahmen der Routine-Pharmakovigilanz bei Intratect 100 g/l behandelten Patienten; Therapie im Rahmen der Zulassung

Psychische Belastung von Krebspatienten im Verlauf der ambulanten onkologischen Behandlung

Phase II trial of Pembrolizumab in COmbination with salvage chemotherapy for first-RElapsed or refractory classical Hodgkin lymphoma

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480 (BMS-986348), Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

Anwendung von Privigen® bei sekundärer Immunschwäche: Eine multizentrische Beobachtungsstudie (IgPro10_5008)